Long-Term Evolution of Metabolic Status in Patients with Schizophrenia Stably Maintained on Second-Generation Antipsychotics
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Objective Second-generation antipsychotics (SGAs) increase the risk of metabolic syndrome (MetS). Despite the risk of MetS, SGAs may have to be continued with change in some patients. The aim of this study was to trace the evolution of MetS in these patients. Methods Patients with schizophrenia who had been maintained on a fixed SGA regimen for more than a year were followed-up without changing the regimen. Metabolic indicators were evaluated at baseline and at follow-up. Prevalence, incidence and spontaneous normalization rate of MetS were estimated. Risk factors that might have influenced the evolution were scrutinized. Results A total of 151 subjects were included. During the mean observation period of 389.9±162.4 days, the prevalence of MetS was increased from 35.1 to 45.0%. The incidence rate was 29.6%, while the normalization rate was 26.4%, risk factors affecting incidence were age (OR=1.09, 95% CI: 1.03–1.17), baseline continuous values of metabolic syndrome risk scores (cMetS, OR=1.77, 95% CI:1.29– 2.55) and baseline body weight (OR=1.06, 95% CI: 1.01–1.13). Normalization was influenced by age (OR=0.74, 95% CI: 0.57–0.89) and baseline body weight (OR=0.85, 95% CI: 0.72–0.95). Conclusion The prevalence of MetS steadily increased with the continuous use of SGAs. However, individual difference was extensive and about a quarter of the patients were able to recover naturally without specific measurements.
Abstract
Objective Second-generation antipsychotics (SGAs) increase the risk of metabolic syndrome (MetS). Despite the risk of MetS, SGAs may have to be continued with change in some patients. The aim of this study was to trace the evolution of MetS in these patients. Methods Patients with schizophrenia who had been maintained on a fixed SGA regimen for more than a year were followed-up without changing the regimen. Metabolic indicators were evaluated at baseline and at follow-up. Prevalence, incidence and spontaneous normalization rate of MetS were estimated. Risk factors that might have influenced the evolution were scrutinized. Results A total of 151 subjects were included. During the mean observation period of 389.9±162.4 days, the prevalence of MetS was increased from 35.1 to 45.0%. The incidence rate was 29.6%, while the normalization rate was 26.4%, risk factors affecting incidence were age (OR=1.09, 95% CI: 1.03–1.17), baseline continuous values of metabolic syndrome risk scores (cMetS, OR=1.77, 95% CI:1.29– 2.55) and baseline body weight (OR=1.06, 95% CI: 1.01–1.13). Normalization was influenced by age (OR=0.74, 95% CI: 0.57–0.89) and baseline body weight (OR=0.85, 95% CI: 0.72–0.95). Conclusion The prevalence of MetS steadily increased with the continuous use of SGAs. However, individual difference was extensive and about a quarter of the patients were able to recover naturally without specific measurements.
참고문헌 (42)
- Saha S, "A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time?", Arch Gen Psychiatry, 64, pp.1123~1131 (2007)[DOI]
- Osby U, "Time trends in schizophrenia mortality in Stockholm county, Sweden: cohort study", BMJ, 321, pp.483~484 (2000)[DOI]
- Davis JM, "A meta-analysis of the efficacy of secondgeneration antipsychotics", Arch Gen Psychiatry, 60, pp.553~564 (2003)[DOI]
- Kane JM, "Pharmacologic treatment of schizophrenia", Dialogues Clin Neurosci, 12, pp.345~357 (2010)
- Leucht S, "Second-generation antipsychotics for schizophrenia: can we resolve the conflict?", Psychol Med, 39, pp.1591~1602 (2009)[DOI]
- Papanastasiou E, "The prevalence and mechanisms of metabolic syndrome in schizophrenia: a review", Ther Adv Psychopharmacol, 3, pp.33~51 (2013)[DOI]
- Dunkley AJ, "Effectiveness of interventions for reducing diabetes and cardiovascular disease risk in people with metabolic syndrome: systematic review and mixed treatment comparison meta-analysis", Diabetes Obes Metab, 14, pp.616~625 (2012)[DOI]
- Patel PA, "The natural history of patients with isolated metabolic syndrome", Mayo Clin Proc, 91, pp.623~633 (2016)[DOI]
- Mitchell AJ, "Is the prevalence of metabolic syndrome and metabolic abnormalities increased in early schizophrenia? A comparative meta-analysis of first episode, untreated and treated patients", Schizophr Bull, 39, pp.295~305 (2013)[DOI]
- Lee NY, "The prevalence of metabolic syndrome in Korean patients with schizophrenia receiving a monotherapy with aripiprazole, olanzapine or risperidone. Prog Neuropsychopharmacol", Biol Psychiatry, 35, pp.1273~1278 (2011)
- Lee NY, "The prevalence of metabolic syndrome and its association with alanine aminotransferase in clozapine-treated Korean patients with schizophrenia", Int Clin Psychopharmacol, 28, pp.71~79 (2013)[DOI]
- De Hert M, "Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review", Schizophr Res, 101, pp.295~303 (2008)[DOI]
- L'Italien GJ, "Comparison of metabolic syndrome incidence among schizophrenia patients treated with aripiprazole versus olanzapine or placebo", J Clin Psychiatry, 68, pp.1510~1516 (2007)[DOI]
- Srisurapanont M, "Metabolic syndrome in Thai schizophrenic patients: a naturalistic one-year follow-up study", BMC Psychiatry, 7, pp.14~ (2007)[DOI]
- Meyer JM, "Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1", Schizophr Res, 101, pp.273~286 (2008)[DOI]
- Saddichha S, "Metabolic syndrome in first episode schizophrenia-a randomized double-blind controlled, short-term prospective study", Schizophr Res, 101, pp.266~272 (2008)[DOI]
- Graham KA, "Early treatment-related changes in diabetes and cardiovascular disease risk markers in first episode psychosis subjects", Schizophr Res, 101, pp.287~294 (2008)[DOI]
- Ventriglio A, "Metabolic issues in patients affected by schizophrenia: clinical characteristics and medical management", Front Neurosci, 9, pp.297~ (2015)
- Kelly AC, "A naturalistic comparison of the long-term metabolic adverse effects of clozapine versus other antipsychotics for patients with psychotic illnesses", J Clin Psychopharmacol, 34, pp.441~445 (2014)[DOI]
- Schorr SG, "The incidence of metabolic syndrome and its reversal in a cohort of schizophrenic patients followed for one year", J Psychiatr Res, 43, pp.1106~1111 (2009)[DOI]
- Steylen PM, "Cardiometabolic comorbidity in antipsychotic treated patients: need for systematic evaluation and treatment", Int J Psychiatry Clin Pract, 17, pp.125~130 (2013)[DOI]
- Mitchell AJ, "Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders-a systematic review and meta-analysis", Schizophr Bull, 39, pp.306~318 (2013)[DOI]
- Vancampfort D, "A meta-analysis of cardio-metabolic abnormalities in drug naive, first-episode and multi-episode patients with schizophrenia versus general population controls", World Psychiatry, 12, pp.240~250 (2013)[DOI]
- Vancampfort D, "Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis", World Psychiatry, 14, pp.339~347 (2015)[DOI]
- Rummel-Kluge C, "Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis", Schizophr Res, 123, pp.225~233 (2010)[DOI]
- Bobo WV, "Prediction of longterm metabolic effects of olanzapine and risperidone treatment from baseline body mass index in schizophrenia and bipolar disorder", Psychiatry Res, 189, pp.200~207 (2011)[DOI]
- Hoffmann VP, "Predictive value of early changes in triglycerides and weight for longer-term changes in metabolic measures during olanzapine, ziprasidone or aripiprazole treatment for schizophrenia and schizoaffective disorder post hoc analyses of 3 randomized, controlled clinical trials", J Clin Psychopharmacol, 30, pp.656~660 (2010)
- American Heart Association, "Diagnosis and management of the metabolic syndrome. An American Heart Association", National Heart, Lung, and Blood Institute Scientific Statement. Executive summary, 2005, pp.13, 322~327
- Seo JA, "The cutoff values of visceral fat area and waist circumference for identifying subjects at risk for metabolic syndrome in elderly Korean: Ansan Geriatric (AGE) cohort study", BMC Public Health, 9, pp.443~ (2009)[DOI]
- Eisenmann JC, "On the use of a continuous metabolic syndrome score in pediatric research", Cardiovasc. Diabetol, 7, pp.17~ (2008)[DOI]
- Papaioannou TG, "Mean arterial pressure values calculated using seven different methods and their associations with target organ deterioration in a single-center study of 1878 individuals", Hypertens Res, 39, pp.640~647 (2016)[DOI]
- Kweon S, "Data resource profile: the Korea National Health and Nutrition Examination Survey (KNHANES)", Int J Epidemiol, 43, pp.69~77 (2014)[DOI]
- Ahn YM, "Experience of maintaining clozapine medication in patients with 'red-alert zone' neutropenia: long-term follow-up results", Int Clin Psychopharmacol, 19, pp.97~101 (2004)[DOI]
- Usta NG, "Clozapine treatment of refractory schizophrenia during essential chemotherapy: a case study and mini review of a clinical dilemma", Ther Adv Psychopharmacol, 4, pp.276~281 (2014)[DOI]
- Whitney Z, "Treatment of clozapine-associated weight gain: a systematic review", Eur J Clin Pharmacol, 71, pp.389~401 (2015)[DOI]
- Zimbron J, "A systematic review and meta-analysis of randomised controlled trials of treatments for clozapine-induced obesity and metabolic syndrome", Eur Neuropsychopharmacol, 26, pp.1353~1365 (2016)[DOI]
- Dulloo AG, "Pathways from weight fluctuations to metabolic diseases: focus on maladaptive thermogenesis during catchup fat", Int J Obes Relat Metab Disord, 26(Suppl 2), pp.S46~S57 (2002)[DOI]
- Bai YM, "Association of weight gain and metabolic syndrome in patients taking clozapine: an 8-year cohort study", J Clin Psychiatry, 72, pp.751~756 (2010)
- Krogh J, "Can exercise increase fitness and reduce weight in patients with schizophrenia and depression?", Front Psychiatry, 5, pp.89~ (2014)
- Weber M, "A cognitive", behavioral group intervention for weight loss in patients treated with atypical antipsychotics, 2006, pp.83, 95~101
- Kinon BJ, "Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia", J Clin Psychiatry, 62, pp.92~100 (2001)[DOI]
- Hyuk Sang Kwon, "Prevalence and Clinical Characteristics of the Metabolic Syndrome in Middle-Aged Korean Adults; Chungju Insulin Resistance Cohort Study (CIRC Study)", The Korean Journal of Internal Medicine, 20(4), pp.310~316 (2005), 대한내과학회